-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by Analysts
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $42.50.
A number of research analysts have recently commented on the company. Raymond James raised their target price on Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. Needham & Company LLC raised their target price on Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd.
Get Veracyte alerts:Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its stake in shares of Veracyte by 25.0% in the second quarter. Legal & General Group Plc now owns 372,125 shares of the biotechnology company's stock worth $7,405,000 after purchasing an additional 74,329 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Veracyte by 121.5% in the second quarter. Goldman Sachs Group Inc. now owns 1,049,845 shares of the biotechnology company's stock worth $20,892,000 after purchasing an additional 575,949 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Veracyte by 712.9% in the second quarter. Captrust Financial Advisors now owns 3,219 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,823 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Veracyte by 8.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 31,036 shares of the biotechnology company's stock worth $618,000 after purchasing an additional 2,537 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Veracyte in the second quarter worth $4,127,000.
Veracyte Stock Down 2.0 %
VCYT opened at $16.71 on Friday. The stock has a market cap of $1.20 billion, a PE ratio of -24.57 and a beta of 1.17. The business has a 50 day moving average of $22.74 and a 200-day moving average of $22.22. Veracyte has a 52 week low of $14.85 and a 52 week high of $54.13.Veracyte (NASDAQ:VCYT – Get Rating) last released its earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The company had revenue of $72.86 million during the quarter, compared to analysts' expectations of $67.37 million. Veracyte had a negative return on equity of 4.05% and a negative net margin of 18.13%. Equities analysts anticipate that Veracyte will post -0.8 EPS for the current year.
About Veracyte
(Get Rating)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Further Reading
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $42.50.
据市场评级公司报道,目前跟踪Veracyte公司的九位分析师对该公司股票的平均评级为“中等买入”。一名投资分析师对该股给予了卖出建议,六名分析师给出了买入建议。在过去一年发布该股报告的分析师中,平均12个月的价格目标是42.50美元。
A number of research analysts have recently commented on the company. Raymond James raised their target price on Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. Needham & Company LLC raised their target price on Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd.
一些研究分析师最近对该公司发表了评论。雷蒙德·詹姆斯在8月4日周四的一份研究报告中将Veracyte的目标价从30.00美元上调至31.00美元,并给予该公司“跑赢大盘”的评级。8月3日,Needham&Company LLC在一份研究报告中将Veracyte的目标价从26.00美元上调至31.00美元,并给予该公司“买入”评级。
Institutional Inflows and Outflows
机构资金流入和流出
Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its stake in shares of Veracyte by 25.0% in the second quarter. Legal & General Group Plc now owns 372,125 shares of the biotechnology company's stock worth $7,405,000 after purchasing an additional 74,329 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Veracyte by 121.5% in the second quarter. Goldman Sachs Group Inc. now owns 1,049,845 shares of the biotechnology company's stock worth $20,892,000 after purchasing an additional 575,949 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Veracyte by 712.9% in the second quarter. Captrust Financial Advisors now owns 3,219 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,823 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Veracyte by 8.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 31,036 shares of the biotechnology company's stock worth $618,000 after purchasing an additional 2,537 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Veracyte in the second quarter worth $4,127,000.
大型投资者最近增持或减持了该股。Legal&General Group Plc在第二季度将其在Veracyte的股份增加了25.0%。Legal&General Group Plc现在拥有这家生物技术公司372,125股股票,价值7,405,000美元,上个季度又购买了74,329股。高盛股份有限公司在第二季度增持了121.5%的Veracyte股份。高盛股份有限公司现在持有这家生物技术公司1,049,845股股票,价值20,892,000美元,该公司在上个季度又购买了575,949股。CapTrust Financial Advisors在第二季度将其在Veracyte的股票持股比例提高了712.9。CapTrust Financial Advisors现在持有这家生物技术公司3219股股票,价值6.4万美元,在上个季度又购买了2823股。Price T Rowe Associates Inc.MD在第二季度将其在Veracyte股票的持股比例提高了8.9%。Price T Rowe Associates Inc.MD现在拥有31,036股这家生物技术公司的股票,价值618,000美元,此前在上个季度又购买了2,537股。最后,保诚金融公司在第二季度购买了价值4,127,000美元的Veracyte新股票头寸。
Veracyte Stock Down 2.0 %
Veracyte股价下跌2.0%
Veracyte (NASDAQ:VCYT – Get Rating) last released its earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The company had revenue of $72.86 million during the quarter, compared to analysts' expectations of $67.37 million. Veracyte had a negative return on equity of 4.05% and a negative net margin of 18.13%. Equities analysts anticipate that Veracyte will post -0.8 EPS for the current year.
Veracyte(纳斯达克:VCyT-GET Rating)上一次发布财报是在8月2日(星期二)。这家生物技术公司公布了该季度每股收益(0.13美元),比分析师普遍预期的(0.21美元)高出0.08美元。该公司当季营收为7,286万美元,高于分析师预期的6,737万美元。Veracyte的净资产回报率为负4.05%,净利润率为负18.13%。股票分析师预计,Veracyte本年度每股收益将达到0.8%。
About Veracyte
关于Veracyte
(Get Rating)
(获取评级)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Veracyte,Inc.是一家全球性的诊断公司。该公司提供Afirma基因组测序分类器和Xpression Atlas,用于确定结果不确定的患者是否为良性疾病,以避免不必要的手术;解密前列腺癌活检和根治性前列腺癌切除术;Prosigna乳腺癌检测用于乳腺癌诊断;Percepta基因组测序分类器和Percepta鼻拭子测试用于肺癌诊断;Envisia基因组分类器用于诊断间质性肺部疾病,包括特发性肺纤维化;免疫结肠癌检测用于结肠癌诊断。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase's Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于Veracyte的研究报告(VCyT)
- 这些机构持有达顿餐饮国际公司的股份
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
- 住房建设的黄金时代已经结束了吗?
- 这三大股利支付者也拥有强劲的价格增长
- 天然气价格继续回升,这些股票应该会受益
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Veracyte Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Veracyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧